About this trial
Transcranial magnetic stimulation (TMS) is a widely used tool for exploring brain function in humans (Siebner et al. et al., 2022), which has led to new therapeutics for various psychiatric and neurological disorders (Lefaucheur et al., 2020). However, the open-loop use of this technique has raised questions about its operating principle, due to the high degree of heterogeneity of results and the small to medium observed effect sizes (Zrenner and Ziemann, 2023). To increase the response rate, it has been suggested to individualize stimulation, by adapting the TMS parameters (i.e. delivered dose, target dose, targeting, timing, etc.) to instantaneous estimates of brain brain state. Such an approach, known as closed-loop closed-loop stimulation, is currently one of the main challenges challenges in this field (closed-loop brain state-dependent stimulation). To this end, we are focusing on the combination of robotic TMS and electroencephalography (EEG) (Hernandez-Pavon et al. al., 2023). The closed-loop stimulations using this combination developed to date have two limitations: (i) they are not adaptive and focus focus mainly on calculating the phase of brain oscillations to trigger stimulation and (ii) are limited to central cortical (sensorimotor) areas, where the EEG signal-to-noise ratio is optimal.
This project aims to develop closed-loop TMS-EEG protocols that overcome these two limitations: (i) by incorporating adaptive decision modeling (AutoHS model, Harquel et al. 2017) to optimize several parameters in parallel (coil location, orientation, intensity) while using a wider range of EEG markers (evoked potentials, oscillatory activity strength, connectivity, etc.), and (ii) by integrating real-time EEG pre-processing to access any cortical target (including frontal, temporal and occipital lobes).
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Signed informed consent
Having undergone a medical examination prior to participation in research
Affiliation with or beneficiary of a social security scheme
Disqualifiers
Contraindications (CI) to MRI, EEG, TMS practice
Existence of a severe general medical condition: cardiac, respiratory, hematological, renal, hepatic, cancerous,
Regular use of anxiolytics, sedatives, antidepressants, neuroleptics,
Characterized psychiatric pathology,
Trial population
Healthy volunteers from Grenoble and the surrounding area
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Quality of EEG markers extracted in real-time
Quality of EEG markers extracted in real-time (evoked potentials, power and phase of brain oscillations and functional connectivity)
Quality of EEG marker modulation
Quality of EEG marker modulation induced by TMS parameters selected by the AutoHS decision model
Secondary outcomes
Intra-individual (inter-session) reproducibility of primary endpoint quality markers
Intra-individual (inter-session) reproducibility of primary endpoint quality markers
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University Hospital, Grenoble
Lead sponsor
Laboratoire de Psychologie et NeuroCognition (LPNC), Université Grenoble Alpes
Collaborator
GIPSA-lab, Grenoble, France
Collaborator
This trial is not recruiting at the moment. You can still explore other options: